CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation

Clin Transl Med. 2023 Oct;13(10):e1459. doi: 10.1002/ctm2.1459.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytomegalovirus
  • Epstein-Barr Virus Infections*
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Herpesvirus 4, Human
  • Humans
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
  • Receptors, Chimeric Antigen* / genetics
  • Sialic Acid Binding Ig-like Lectin 2
  • Viremia

Substances

  • Receptors, Chimeric Antigen
  • CD22 protein, human
  • Sialic Acid Binding Ig-like Lectin 2